Orexo Interim Report Q4 2023, incl. Full Year Report
UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 23.4 m...
UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 23.4 m...
